Top Medical Searches

Pfizer’s biosimilar of Amgen, J&J’s anemia treatments gets FDA nod

(Reuters) – Pfizer Inc’s Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.

 Read more…

Be Sociable, Share!
May 16th, 2018 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us